IPO Year: 2024
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/19/2026 | Peer Perform | Wolfe Research | |
| 12/11/2025 | $70.00 | Outperform | Wedbush |
| 11/24/2025 | Buy | Truist | |
| 10/8/2025 | $90.00 | Buy | Guggenheim |
| 8/19/2025 | $55.00 | Overweight | Piper Sandler |
| 7/10/2025 | $40.00 | Buy | Goldman |
| 5/2/2025 | $41.00 | Overweight | Analyst |
| 4/16/2025 | $23.00 | Sector Perform | Scotiabank |
| 1/7/2025 | Buy | TD Cowen | |
| 10/24/2024 | $60.00 | Buy | UBS |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Wolfe Research initiated coverage of CG Oncology with a rating of Peer Perform
Wedbush initiated coverage of CG Oncology with a rating of Outperform and set a new price target of $70.00
Truist initiated coverage of CG Oncology with a rating of Buy
Guggenheim initiated coverage of CG Oncology with a rating of Buy and set a new price target of $90.00
Piper Sandler initiated coverage of CG Oncology with a rating of Overweight and set a new price target of $55.00
Goldman resumed coverage of CG Oncology with a rating of Buy and set a new price target of $40.00
Analyst initiated coverage of CG Oncology with a rating of Overweight and set a new price target of $41.00
Scotiabank initiated coverage of CG Oncology with a rating of Sector Perform and set a new price target of $23.00
TD Cowen initiated coverage of CG Oncology with a rating of Buy
UBS initiated coverage of CG Oncology with a rating of Buy and set a new price target of $60.00
8-K - CG Oncology, Inc. (0001991792) (Filer)
SCHEDULE 13G - CG Oncology, Inc. (0001991792) (Subject)
SCHEDULE 13G - CG Oncology, Inc. (0001991792) (Subject)
10-Q - CG Oncology, Inc. (0001991792) (Filer)
8-K - CG Oncology, Inc. (0001991792) (Filer)
DEFA14A - CG Oncology, Inc. (0001991792) (Filer)
DEF 14A - CG Oncology, Inc. (0001991792) (Filer)
144 - CG Oncology, Inc. (0001991792) (Subject)
8-K - CG Oncology, Inc. (0001991792) (Filer)
SCHEDULE 13G/A - CG Oncology, Inc. (0001991792) (Subject)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - CG Oncology, Inc. (0001991792) (Issuer)
4/A - CG Oncology, Inc. (0001991792) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Fastest customizable press release news feed in the world
4 - CG Oncology, Inc. (0001991792) (Issuer)
4 - CG Oncology, Inc. (0001991792) (Issuer)
4 - CG Oncology, Inc. (0001991792) (Issuer)
4 - CG Oncology, Inc. (0001991792) (Issuer)
4 - CG Oncology, Inc. (0001991792) (Issuer)
4 - CG Oncology, Inc. (0001991792) (Issuer)
4 - CG Oncology, Inc. (0001991792) (Issuer)
4 - CG Oncology, Inc. (0001991792) (Issuer)
4 - CG Oncology, Inc. (0001991792) (Issuer)
4 - CG Oncology, Inc. (0001991792) (Issuer)
DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference this month. The details of the upcoming events are as follows: Jefferies Global Healthcare Conference Date: Wednesday, June 3, 2026Presentation Time: 10:30-11:00 AM ETLocation: New York, New York Goldman Sachs 47th Annual Global Healthcare Conference Date: Tuesday, June 9, 2026Presentation Time: 2:40-3:15 PM ETLocation: Miami, Florida Interested parties may access the live audio we
Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBCLast year's awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder canc
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat population was 96.0% at 3 months and 89.5% at 6 months - Efficacy was comparable across concurrent and sequential treatment arms and across both BCG-exposed and BCG-Unresponsive populations DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced positive first results from CORE‑008 Cohort CX, a Phase 2 study evaluating intravesical cretostimogene grenadenorepvec in combination with gemcitabine sequential versus concurrent treatment schedules in
-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented- -Visit CG Oncology at booth #3051- DALLAS, May 11, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced its participation in the American Urological Association (AUA) 2026 Annual Meeting, taking place May 15–18, 2026, in Washington, D.C. CG Oncology will present first results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients and will be exhibiting at booth #3051. The AUA Annual Meeting is the largest global gatherin
Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated first half 2026CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) NMIBC BCG-exposed and BCG-unresponsive to be presented at AUA 2026Well-positioned to deliver on key milestones with approximately $1.1 billion cash, cash equivalents and marketable securities sufficient to fund operations through 2029 DALLAS, May 08, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today reported fin
DALLAS, May 05, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will participate in fireside chat presentations at the Bank of America Health Care Conference and the RBC Capital Markets Global Healthcare Conference this month. The details of the upcoming events are as follows: Bank of America Health Care Conference 2026Date: Tuesday, May 12, 2026Presentation Time: 10:40 AM – 11:10 AM PTLocation: Las Vegas, NV RBC Capital Markets Global Healthcare ConferenceDate: Wednesday, May 20, 2026Presentation Time: 2:35 PM – 3:00 PM ETLocation: New York, NY Interest
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) NMIBC expected first half 2026Well-positioned to deliver on key milestones with approximately $903.0 million cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2029 IRVINE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today reported financial results for the fourth quarter and year ended December 31, 2025, and provided business updates. "In the coming month
IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 3:10 pm ET. The conference is taking place at the Boston Marriott Copley Place in Boston, MA. Interested parties may access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available shortly after the conclusion of the live presentation and archived for approximately 90 days. About CG Onco
SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. These appointments are expected to enhance the Company's operational, clinical, and regulatory capabilities as Oncolytics advances registration-directed development programs in pancreatic, colorectal, and anal cancers. Mr. McAdory will oversee clinical development execution, operational strategy, and regulatory readiness across the Company's portfolio. He br
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. 12, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The oncology landscape is entering a high-velocity regulatory phase as genomics in cancer care expands toward a projected $69.16 billion by 2032[1]. This massive growth is driven by the systematic integration of genotype-directed treatment pathways into standard medical practice. The precision medicine market is now on a trajectory to expand from $138.67 billion in 2026 to over $537.17 billion by 2035[2]. This strategic pivot toward registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), CG Oncology (NASDAQ:CGON), Ze
Live Leadership Updates
SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. These appointments are expected to enhance the Company's operational, clinical, and regulatory capabilities as Oncolytics advances registration-directed development programs in pancreatic, colorectal, and anal cancers. Mr. McAdory will oversee clinical development execution, operational strategy, and regulatory readiness across the Company's portfolio. He br
- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the appointment of Christina Rossi to its Board of Directors. Additionally, Simone Song, Senior Partner, ORI Capital, has resigned from the Board effective November 22, 2025. "We are at a critical juncture in CG Oncology's history with our recent BLA initiation for cretostimogene. Now we are laying the foundation for a successful
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,
Live finance-specific insights
- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients remained free from progression to MIBC at 24 months– - 91.6% of responders remained cystectomy-free at 24 months – - No Grade 3 or greater treatment-related adverse events or deaths reported – - Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M – - Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025 - IRVINE, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:C
IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) to be presented on April 26, 2025, at a Plenary Session at the American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. Individuals can access the webcast via the link on
- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve (Cohort A) and BCG-Exposed (Cohort B) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress - - Completed Oversubscribed $238 Million Follow-on Public Equity Offering that Extends Expected Runway into the First Half of 2028 - IRVINE, Calif., March 28, 2025 (GLOBE NEWS
– 74.5% of patients achieved a complete response at any time – – Median duration of response is greater than 27 months and not reached – – Latest data update continued to show favorable safety and tolerability results – – Company hosting virtual investor event with lead investigator at 8 am EST today – IRVINE, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unr
IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 7 am CST on December 5, 2024, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In addition to company executives, this call will feature Mark Tyson, II, M.D., M.P.H., urologic oncologist at Mayo Clinic, and lead investigator in the BOND-003 study. Dr. Tyson is presenti
- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today at 4:30pm EDT - IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. today announced that data from the Phase 3 BOND-003 study evaluating the efficacy and safety of cretostimogene monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG), showed that 75.2% of patients (79 out of 105 [95% confidence interval (CI), 65-83]) achieved a complete response (CR) at any time, as of the cutoff date of April 1, 202
This live feed shows all institutional transactions in real time.
SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)
SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)
SC 13G - CG Oncology, Inc. (0001991792) (Subject)
SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)
SC 13G - CG Oncology, Inc. (0001991792) (Subject)